MARTINSRIED/MUNICH, Germany and SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (German Stock Exchange (Frankfurt), Prime Standard: MDG) (MDGGn.DE) announced today that the Company will be presenting at the Annual BIO CEO & Investor Conference in New York on Wednesday, February 15, 2006 at 1 p.m. local time at the New York Waldorf Astoria Hotel. The presentation will be given by Dr. Peter Heinrich, Chief Executive Officer of MediGene. The presentation will be webcast live and will be accessible through the MediGene website at http://www.medigene.com/. A replay will be available via the website following the live event. MediGene possesses a mature drug pipeline with one drug available on the German market with a pan-European roll out in preparation as well as a number of additional drug candidates in all stages of clinical development (phases I - III). This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) is a trademark of MediGene AG, Eligard(R) is a trademark of QLT USA, Inc. (formerly Atrix). DATASOURCE: MediGene AG CONTACT: Thomas Fechtner, +1-212-477-9007, ext. 31 for MediGene AG Web site: http://www.medigene.com/

Copyright